Extrahepatic bile duct carcinoma
MONDO:0003090A carcinoma that arises from epithelial cells of the extrahepatic bile duct.
Also known as: carcinoma of extrahepatic bile duct, carcinoma of the extrahepatic bile duct, extrahepatic bile duct cancer, extrahepatic bile duct carcinoma
3329 clinical trials for this condition and its sub-types, 51 tagged with Extrahepatic bile duct carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Extrahepatic bile duct carcinoma
-
Extrahepatic bile duct adenocarcinoma 2 trials · 409 incl. sub-types
7 sub-types
- Adenocarcinoma of gallbladder and extrahepatic biliary tract 6 trials · 374 incl. sub-types Sub-types →
- Ampulla of vater adenocarcinoma 11 trials · 42 incl. sub-types Sub-types →
- Extrahepatic bile duct clear cell adenocarcinoma 0 trials Sub-types →
- Extrahepatic bile duct mucinous adenocarcinoma 0 trials Sub-types →
- Extrahepatic bile duct signet ring cell carcinoma 0 trials Sub-types →
- Extrahepatic bile duct small cell adenocarcinoma 0 trials
- Papillary extrahepatic bile duct adenocarcinoma 0 trials
-
Carcinoma of the ampulla of vater 29 trials · 65 incl. sub-types
3 sub-types
- Ampulla of vater adenocarcinoma 11 trials · 42 incl. sub-types Sub-types →
- Ampulla of vater small cell neuroendocrine carcinoma 0 trials
- Ampulla of vater squamous cell carcinoma 0 trials Sub-types →
-
Distal biliary tract carcinoma 32 trials
Most studied deeper sub-types
-
Freezing tumors plus dual immunotherapy: a new attack on bile duct cancer
Disease control Not yet recruitingResearchers are testing whether adding cryoablation, a procedure that freezes tumors, to two drugs can help people with advanced biliary tract cancer that worsened after first-line treatment. The drugs are QL1706, a dual immunotherapy, and lenvatinib, a targeted therapy. The tria…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Can a targeted pill shrink hard-to-treat bile duct cancers?
Disease control Not yet recruitingThis phase 2 trial tests whether daraxonrasib, an oral drug that targets cancers with a KRAS mutation, can shrink tumors in people with advanced biliary tract cancer that has progressed after first-line treatment. Participants take the drug once daily in 28-day cycles. The main g…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a Dual-Action antibody boost chemo against bile duct cancer?
Disease control Not yet recruitingThis trial is testing whether adding ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works better than the usual chemo-immunotherapy combination for people with advanced biliary tract cancer. Ivonescimab is a special antibody that targets two proteins: one that h…
Phase 2/3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can matching drugs to tumor genes beat biliary cancer?
Disease control Not yet recruitingThis umbrella trial is testing whether assigning treatment based on a person's tumor genetics can improve outcomes for advanced biliary tract cancers. Participants receive one of several targeted therapies or immunotherapy, depending on their genetic test results. The study aims …
Phase 2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New hope for bile duct cancer: combo therapy aims to boost survival
Disease control Not yet recruitingThis study tests whether adding the drug Mitazalimab to standard chemotherapy helps people with advanced bile duct cancer live longer. About 160 adults whose cancer has spread or cannot be removed will receive either chemo alone or chemo plus Mitazalimab. Researchers will check s…
Phase 2/3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cocktail of drugs targets Hard-to-Treat bile duct cancer
Disease control Not yet recruitingThis phase 2 trial tests a combination of three drugs—disitamab vedotin, lenvatinib, and a PD-1 inhibitor—for people with HER2-positive advanced biliary tract cancer that cannot be removed by surgery. The study will enroll 65 participants to see how well the treatment shrinks tum…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:45 UTC
-
Bile may hold the key to guiding targeted treatment for bile duct and gallbladder cancers
Diagnosis Not yet recruitingResearchers want to know whether leftover bile fluid can reveal genetic changes in tumors of people with advanced biliary tract cancer, such as bile duct or gallbladder cancer. Collecting tumor tissue for genetic testing can be difficult or risky in this cancer, so the study coll…
Sponsor: CHA University • Aim: Diagnosis
Last updated Sep 21, 2026 17:00 UTC
-
Herbal pill may ease cancer treatment burden
Symptom relief Not yet recruitingThis study tests whether adding a traditional Chinese herbal pill called Yueju to standard cancer therapy can improve quality of life for people with advanced biliary tract cancer. About 210 adults will be randomly assigned to get either the pill or a placebo, without knowing whi…
Sponsor: Fudan University • Aim: Symptom relief
Last updated Jun 26, 2026 16:24 UTC
-
Blood tests and patient surveys could improve bile duct cancer monitoring
Knowledge-focused Not yet recruitingThis study aims to learn if blood tests for cancer DNA (ctDNA) and patient-reported quality of life can help doctors predict how bile duct cancer will progress and whether treatments are working. Researchers will collect blood samples and surveys from 300 patients with curable or…
Sponsor: Aarhus University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC